ADARx Pharmaceuticals (NASDAQ:ADRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of ADARx Pharmaceuticals (NASDAQ:ADRX) to a hold rating in a report published on Saturday morning,Wall Street Zen reports.

ADARx Pharmaceuticals Price Performance

Shares of NASDAQ ADRX opened at $19.05 on Friday. ADARx Pharmaceuticals has a 1-year low of $17.30 and a 1-year high of $23.21.

Insider Activity

In other news, Director Simeon George bought 1,600,000 shares of the stock in a transaction on Monday, September 28th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $27,200,000.00. Following the completion of the purchase, the director directly owned 5,554,094 shares in the company, valued at approximately $94,419,598. The trade was a 40.46% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Erez Chimovits purchased 61,516 shares of the business’s stock in a transaction on Monday, September 28th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $1,045,772.00. Following the completion of the acquisition, the director directly owned 9,292,025 shares of the company’s stock, valued at approximately $157,964,425. The trade was a 0.67% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 3,261,516 shares of company stock worth $55,445,772.

ADARx Pharmaceuticals Company Profile

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing RNA-based medicines for immune-mediated and other serious diseases. The company is headquartered in San Diego, California, and uses proprietary technologies designed to modulate disease-related proteins at the RNA level.

ADARx’s pipeline includes investigational therapies intended to address conditions involving the complement system, coagulation pathways and other biologic mechanisms. Its programs are designed to provide targeted, durable treatment through approaches such as RNA interference and related forms of RNA-based therapeutic intervention.

Founded in 2018, ADARx has advanced its drug candidates through preclinical and clinical development and has pursued regulatory and clinical activities in the United States and other international markets.